- XORTX Therapeutics Inc (XORTX) is a drug development company primarily focused on orphan disease indications which have a uric acid imbalance as well as metabolic syndrome, diabetes and diabetic nephropathy.
- XORTX possesses patents and patent applications that include US and Worldwide rights for the development of uric acid lowering agents for the treatment of Hypertension, Insulin Resistance, Diabetes, Metabolic Syndrome and Kidney Injury – large market opportunities.
- Strong clinical and scientific evidence shows that chronically increased serum uric acid can cause a ‘disease axis’ that includes obesity, high blood pressure, widespread activation of inflammation, progressive kidney injury, and progressive diabetes symptoms. Treatment of this recently defined, new and harmful mechanism of action has been patented by XORTX.
- Investigator Led Phase II Clinical studies have verified that treating and lowering chronically increased uric acid levels in the blood may be an important new approach to managing disease caused by uric acid. Some of those studies include Phase II studies showing that lowering and maintaining uric acid can block weight gain and decrease blood pressure, while other studies – three phase II studies – show substantial improvement of kidney dysfunction when uric acid is controlled.
- XORTX is developing oxypurinol, a uric acid lowering agent. This uric acid lowering agent has a well established safety and effectiveness profile which the FDA previously allowed for treating gout on a compassionate basis, when patients could not tolerate Allopurinol. This clinical experience with oxypurinol demonstrated that oxypurinol is safe and effective for lowering uric acid. Thus, oxypurinol is ideally suited for development to treat orphan indications like polycystic kidney disease and will benefit from 7 years marketing exclusivity in the US, if approved by the FDA.